NASDAQ:INO - Inovio Pharmaceuticals, Inc.
$3.73
 $0.01
+0.27%
4:00PM EDT
2019-04-18
Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  INO     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 79   203. 85   241. 91  
42 stocks rank:  3. 53 K 1. 44 K 1. 05 K
# analyst opinions:  8. 00   14. 51   13. 97  
mean recommendation:  1. 60   2. 09   2. 01  

quick ratio:  2. 42   5. 27   1. 81  
current ratio:  2. 49   5. 62   2. 25  

target price low:  7. 00   84. 80   115. 21  
target price avg:  10. 75   111. 51   137. 51  
target price high:  4. 14   135. 81   157. 84  
1-yr high:  6. 11   114. 23   138. 78  
last close:  3. 73   87. 66   116. 69  
50-day avg:  3. 82   95. 54   123. 44  
200-day avg:  4. 59   94. 25   121. 11  
1-yr low:  3. 34   72. 78   98. 34  
volume:  1. 28 M 4. 11 M 8. 07 M
50-day avg volume:  1. 56 M 2. 76 M 5. 02 M
200-day avg volume:  1. 06 M 2. 92 M 4. 59 M

1-day return:  0. 27 % -0. 41 % 0. 07 %
this week return:  -9. 02 % -5. 74 % -4. 11 %
12-wk return:  -26. 86 % 1. 61 % -0. 05 %
52-wk return:  -20. 34 % 3. 12 % 8. 78 %

enterprise value (EV):  283. 05 M 48. 94 B 114. 64 B
market cap:  365. 29 M 43. 07 B 104. 73 B
EBITDA:  -89. 09 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -3. 18   4. 22   12. 73  
enterprise/revenue (EV/R):  9. 29   63. 17   12. 84  
total revenue:  30. 48 M 10. 62 B 38. 47 B
total debt:  0. 00   12. 24 B 16. 73 B
net income (common):  -96. 97 M 2. 20 B 4. 20 B

shares outstanding:  97. 93 M 571. 70 M 1. 24 B
shares:  91. 65 M 571. 81 M 1. 23 B
shares short:  13. 49 M 10. 17 M 13. 00 M
shares short prior month:  9. 39 M 9. 54 M 17. 33 M
short ratio:  9. 03   5. 41   3. 28  
short % of float:  14. 65 % 5. 45 % 2. 38 %
total cash/share:  0. 83   11. 14   9. 33  
total cash:  81. 23 M 6. 71 B 7. 15 B
free cash flow:  -40. 99 M 3. 58 B 2. 96 B
operating cash flow:  -73. 55 M 4. 15 B 4. 30 B

book value:  0. 89   12. 78   26. 92  
price/book:  4. 17   3. 06   -1. 74  
gross profits:  -64. 78 M 8. 04 B 34. 86 B
operating margins:  -308. 68 % -725. 35 % -89. 04 %
EBITDA margins:  -292. 29 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  -212. 51 % 37. 08 % 55. 70 %

1-yr max volatility:  -21. 15 % --- ---
1-yr mean volatility:  -0. 03 % 0. 03 % 0. 04 %

1-yr EPS:  -1. 05   2. 40   4. 10  
forward EPS:  -1. 09   3. 97   7. 13  
P/E:  -3. 55   13. 63   22. 72  
forward P/E:  -3. 42   -15. 95   13. 99  
PE/G:  0. 05   -1. 65   -1. 32  
growth:  -71. 50 % 127. 12 % 29. 61 %
earnings high:  -0. 14   1. 00   1. 66  
earnings avg:  -0. 26   0. 77   1. 53  
earnings low:  -0. 32   0. 50   1. 39  
revenue high:  15. 83 M 2. 68 B 10. 78 B
revenue avg:  6. 41 M 2. 59 B 10. 57 B
revenue low:  2. 45 M 2. 49 B 10. 36 B
return on assets:  -36. 94 % -2. 75 % 4. 55 %
return on equity:  -84. 50 % -18. 45 % 5. 46 %
revenue growth:  -71. 50 % 92. 86 % 18. 96 %
revenue/share:  0. 33   13. 29   55. 46  

beta (1yr vs S&P500):  1. 34   1. 25   0. 93  
sharpe (1yr):  -0. 14   0. 37   0. 70  

held % insiders:  6. 28 % 6. 39 % 3. 38 %
held % institutions:  37. 49 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : INO
.    + 0.881 =         0.881 :: INITIAL WEIGHT
.   + 42.569 =         43.45 :: spline projection addition
.    x 1.431 =        62.195 :: industry recommendation factor
.    x 2.844 =       176.902 :: symbol recommendation factor
.    x 1.147 =       202.905 :: EV/R factor
.    x 0.996 =       202.155 :: return on assets factor
.    x 0.992 =       200.447 :: return on equity factor
.    x 0.993 =       199.014 :: revenue growth factor
.    x 2.442 =       486.065 :: current ratio factor
.    x 1.306 =       634.909 :: quick ratio factor
.    x 1.054 =       669.141 :: short ratio factor
.    x 2.042 =      1366.201 :: price-to-book factor
.    x 1.021 =      1394.346 :: 5-day avg > 50-day avg
.    x 2.115 =      2948.578 :: P/E weight
.    x 2.118 =      6245.385 :: PE/G factor
.    x 1.469 =      9172.305 :: beta factor
.    x 0.138 =      1265.231 :: sharpe factor
.    x 2.039 =      2579.746 :: target low factor
.    x 1.457 =      3759.441 :: target mean factor
.    x 1.033 =      3883.782 :: target high factor
.     x 1.31 =      5087.319 :: industry 2-weeks return factor
.    x 0.952 =      4842.401 :: "drift" penalty 2 days ago
.    x 0.925 =      4480.437 :: "drift" penalty 4 days ago
.     x 0.94 =      4209.973 :: overall "drift" factor
.    x 0.999 =      4206.101 :: largest single-day jump factor
.    x 0.074 =       312.721 :: low price factor
.      x 1.0 =       312.671 :: factor hist industry gain for week 16
.   cubeRoot =         6.787 :: reduced to standardize
.   - 20.116 =         0.794 :: add/subtract for performance
.                      0.794 :: FINAL WEIGHT for NASDAQ:INO


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org